Pharmacological management of pulmonary hypertension
| dc.contributor.advisor | Pórszász, Róbert | |
| dc.contributor.advisordept | department of pharmacology and pharmacotherapy. | hu_HU |
| dc.contributor.author | Shammas, Adi | |
| dc.contributor.department | DE--Általános Orvostudományi Kar | hu_HU |
| dc.contributor.opponent | Drimba, László | |
| dc.contributor.opponent | Szentmiklósi, József András | |
| dc.contributor.opponentdept | Kenézy Kórház Központi Aneszteziológiai és Intezív Terápiás Osztály | hu_HU |
| dc.contributor.opponentdept | Debreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet | hu_HU |
| dc.date.accessioned | 2020-02-24T10:41:22Z | |
| dc.date.available | 2020-02-24T10:41:22Z | |
| dc.date.created | 2019-05-13 | |
| dc.description.abstract | Pulmonary hypertension is defined as an elevation in pulmonary arterial pressures (mean pulmonary artery pressure [PAP] ≥25 mmHg or an estimated systolic PAP >36 mmHg). Advances in understanding the pathobiology over the last 2 decades have led to development of both primary therapy (diuretics, digoxin, anticoagulant and oxygen supplementation) and advanced therapy (endothelin receptor antagonists, phosphodiesterase type 5 inhibitors, and prostacyclins) initially directed at reversing the pulmonary vasoconstriction and more recently directed toward reversing endothelial cell dysfunction and smooth muscle cell proliferation. | hu_HU |
| dc.description.course | általános orvos | hu_HU |
| dc.description.courselang | angol | hu_HU |
| dc.description.degree | egységes, osztatlan | hu_HU |
| dc.format.extent | 68 | hu_HU |
| dc.identifier.uri | http://hdl.handle.net/2437/281200 | |
| dc.language.iso | en | hu_HU |
| dc.subject | pulmonay hypertension | hu_HU |
| dc.subject.dspace | DEENK Témalista::Orvostudomány | hu_HU |
| dc.title | Pharmacological management of pulmonary hypertension | hu_HU |